Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

New drug treatments

In this section

The Bio-medical Research Council (BRC), a part of the Oxford Hospital Radcliffe Trust (OHRT), funds research and many of our staff are involved in BRC research.

Our research is funded from a variety of funders. Their support allows our research to focus on the basic and clinical research domains to accelerate knowledge translation from the bedside to the bench, and back again.

pillsWe are currently in an age of unprecedented HCV drug development. Industrial pipelines in this area are remarkable with more than 5 classes of drugs, and greater than 20 compounds, in phase-II or –III trials.  There are industry estimates of more than 150 drugs at various stages of development and new drug regimes suggest that HCV infection will soon become a curable disease for the vast majority.

By collaborating with commercially sponsored clinical trials, and engaging in academic-led clinical studies, STOP-HCV aims to use information gained from new treatment regimes to further understand the virology of HCV infection.   

One such collaboration is the  Gilead-sponsored sofosbuvir trial. The study protocols were developed in close collaboration with STOP-HCV and a significant proportion of the patients enrolled in the study will be recruited in the UK. Samples obtained during the study will be hugely beneficial to the STOP-HCV project.